

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): May 23, 2019

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-33057
(Commission
File Number)

76-0837053
(I.R.S. Employer
Identification No.)

**355 Alhambra Circle
Suite 1250
Coral Gables, Florida**
(Address of principal executive offices)

33134
(Zip Code)

Registrant's telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Name of Exchange on Which Registered</u>	<u>Ticker Symbol</u>
Common Stock, par value \$0.001 per share	NASDAQ Capital Market	CPRX

Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

At the Company's 2019 Annual Meeting of Stockholders held on May 23, 2019, Patrick J. McEnany, Philip H. Coelho, Charles B. O'Keeffe, David S. Tierney, Richard J. Daly and Donald A. Denkhaus were elected to the Company's Board of Directors to serve until the 2020 Annual Meeting of Stockholders or until their successor is duly elected and qualified, or until their earlier death, resignation or removal.

Item 5.07 Submission of Matters to a Vote of Security Holders

On May 23, 2019, the Company held its Annual Meeting of Stockholders at the Hyatt Regency Coral Gables, 50 Alhambra Plaza, Coral Gables, Florida. The final voting results on the matters considered at the meeting are as follows:

1. Election of Directors:

<u>Name</u>	<u>Votes For</u>	<u>Votes Withheld</u>	<u>Broker Non-Votes</u>
Patrick J. McEnany	59,876,973	225,603	34,696,011
Philip H. Coelho	51,084,450	9,018,126	34,696,011
Charles B. O'Keeffe	57,871,148	2,231,428	34,696,011
David S. Tierney	54,915,453	5,187,123	34,696,011
Richard J. Daly	59,712,828	389,748	34,696,011
Donald A. Denkhaus	57,885,970	2,216,606	34,696,011

2. Approval, on an advisory basis, of the 2018 compensation of the Company's Named Executive Officers:

<u>Votes For</u>	<u>Votes Against</u>	<u>Votes Abstained</u>	<u>Broker Non-Votes</u>
59,643,267	231,360	227,949	34,696,011

3. Approval, on an advisory basis, of the frequency of future advisory votes on the compensation of the Company's Named Executive officers:

<u>Every Year</u>	<u>Every Two Years</u>	<u>Every Three Years</u>	<u>Votes Abstained</u>	<u>Broker Non-Votes</u>
53,941,585	136,701	5,716,260	308,030	34,696,011

4. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019:

<u>Votes For</u>	<u>Votes Against</u>	<u>Votes Abstained</u>
92,479,371	1,919,713	399,503

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceuticals, Inc.

By: /s/ Alicia Grande

Alicia Grande

Vice President, Treasurer and Chief Financial Officer

Dated: May 28, 2019